Skip to main content
. 2017 Feb 23;7:43118. doi: 10.1038/srep43118

Figure 6. The results of anti-HER3 targeted therapy.

Figure 6

(a) tumour volumes and (b) mice weights. Mice bearing BxPC-3 xenografts were intraperitoneally injected 3 times per week with 100 μl PBS with 80 μg of 3A3 (treated) or without it (control), n = 6. Mice were implanted at day -7 and treatment was started at day 0 and discontinued at day 30. At time points marked with *tumour volumes in control group were significantly bigger than in treated group (p < 0.05). Results are presented as average for 6 animals ± SD.